HAND2 and triple-negative breast carcinoma: In a study by Min et al, patients with Triple-negative breast cancer (TNBC) had significantly lower plasma levels of lncRNA HAND2-AS1 and were able to act as oncogenes in TNBC by downregulating RUNX 2 to inhibit cancer cell proliferation compared to healthy controls (14).